FULCRUM THERAPEUTICS INC. - COMMON STOCK

Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)

07 Sep 2023 08:00:00 By Nasdaq GlobeNewswire

FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease

22 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Aug 2023 16:53:28 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023

03 Aug 2023 07:01:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Chief Financial Officer

03 Aug 2023 06:55:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Second Quarter 2023 Financial Results Conference Call and Webcast on Thursday, August 3, 2023, at 8:00 a.m. ET

27 Jul 2023 07:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Signs Exclusive Global License Agreement in Rare Hematology

10 Jul 2023 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Jul 2023 17:30:31 By Nasdaq GlobeNewswire

Advocacy and Industry Partners Launch New Global Coalition to Speed Delivery of New Therapies for Facioscapulohumeral Muscular Dystrophy (FSHD)

20 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Jun 2023 16:54:20 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the First Quarter 2023

15 May 2023 07:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Appoints Alex C. Sapir Chief Executive Officer

15 May 2023 07:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host First Quarter 2023 Financial Results Conference Call and Webcast on Monday, May 15, 2023, at 8:00 a.m. ET

08 May 2023 16:05:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

05 May 2023 18:06:50 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

07 Apr 2023 17:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces CFO Resignation

05 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 Mar 2023 17:00:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

09 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2022 Financial Results Conference Call and Webcast on Thursday, March 9, 2023, at 8:00 a.m. ET

06 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Fulcrum Therapeutics Announces Clinical Hold on FTX-6058 in Sickle Cell Disease

24 Feb 2023 08:00:00 By Nasdaq GlobeNewswire